To explore the source of heterogeneity, we perform subgroup analysis in regard to the diagnostic criteria of AKI, prospective or non-prospective design, use of a pre-specified cutoff value of urine output, enrolled high NGAL population, different FST protocols, exclusion or inclusion of patients with baseline CKD, and whether the primary outcome was a pure outcome. Here, LCN2 is linked to chronic kidney disease.